Infliximab for treatment of steroid-refractory ulcerative colitis (Q42686841)

4 November 2017

title

Infliximab for treatment of steroid-refractory ulcerative colitis (English)

1 reference

4 November 2017

Rizzetto M

1 reference

4 November 2017

Actis GC

1 reference

4 November 2017

Bruno M

series ordinal

1 reference

4 November 2017

Pinna-Pintor M

series ordinal

1 reference

4 November 2017

Rossini FP

series ordinal

1 reference

4 November 2017

publication date

1 September 2002

1 reference

Digestive and Liver Disease

4 November 2017

published in

1 reference

4 November 2017

1 reference

4 November 2017

1 reference

4 November 2017

page(s)

631-634

1 reference

Infliximab (Remicade): the magic bullet for Crohn's disease?

4 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980205-5

7 January 2021

Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980205-5

7 January 2021

Infliximab for patients with refractory ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980205-5

7 January 2021

Infliximab for refractory ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980205-5

7 January 2021

Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980205-5

7 January 2021

Infliximab therapy for ulcerative colitis: many unanswered questions

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980205-5

7 January 2021

Cyclosporine in severe ulcerative colitis refractory to steroid therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980205-5

7 January 2021

Intravenous cyclosporin as rescue therapy in severe ulcerative colitis: time for a reappraisal?

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980205-5

7 January 2021

Efficacy and efficiency of oral microemulsion cyclosporin versus intravenous and soft gelatin capsule cyclosporin in the treatment of severe steroid-refractory ulcerative colitis: an open-label retrospective trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980205-5

7 January 2021

Severe steroid-unresponsive ulcerative colitis: outcomes of restorative proctocolectomy in patients undergoing cyclosporin treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980205-5

7 January 2021

Soluble tumour necrosis factor receptors p55 and p75 in the urine monitor disease activity and the efficacy of treatment of inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980205-5

7 January 2021

Histology of colitis: Saguinus oedipus oedipus and other marmosets

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980205-5

7 January 2021

Treatment of ulcerative colitis in the cottontop tamarin using antibody to tumour necrosis factor alpha

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980205-5

7 January 2021

Visceral leishmaniasis in mice devoid of tumor necrosis factor and response to treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980205-5

7 January 2021

Morbidity of medical therapy for ulcerative colitis: what are we really saving?

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980205-5

7 January 2021

Cyclosporine, or cyclosporine not, for severe ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980205-5

7 January 2021

10.1016/S1590-8658(02)80205-5

Identifiers

DOI

1 reference

4 November 2017

1 reference